Street Calls of the Week
Argenx NV ADR has reached an all-time high, with its stock price hitting 781.12 USD. This milestone marks a significant achievement for the company, reflecting a robust performance over the past year. With a market capitalization of $47.26 billion and an impressive 88% revenue growth, the company’s fundamentals support its strong market position. According to InvestingPro data, analysts maintain a strong buy consensus on the stock. The stock has experienced a substantial 41.09% increase over the last 12 months, showcasing investor confidence and strong market demand. Argenx, a biotechnology company known for its innovative therapies, continues to capture the attention of investors as it achieves new heights in the stock market. InvestingPro analysis reveals the company maintains excellent financial health with a score of 3.54 out of 5, and subscribers can access 12 additional exclusive ProTips about ARGX’s performance and outlook.
In other recent news, argenx SE has received increased attention from several analyst firms following positive developments in its research and development efforts. Stifel has raised its price target for argenx to $882, maintaining a Buy rating, due to growing confidence in the company’s pipeline after positive data in seronegative myasthenia gravis. Oppenheimer reaffirmed its Outperform rating on argenx after the ARGX-119 R&D Spotlight event, citing promising clinical proof of concept data in congenital myasthenic syndromes. Truist Securities also reiterated a Buy rating with a price target of $918, expressing optimism about the MuSK agonist opportunity. Furthermore, Truist Securities assumed coverage on argenx, highlighting it as a compelling investment in the biotech sector. BofA Securities maintained its Buy rating and set a price target of $887, noting the strong performance of Vyvgart in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. These developments indicate a positive outlook from analysts regarding argenx’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.